← Leaderboards
Thomas Melendy
State University Of New York At Buffalo
$5,131,088
Attributed
$5,251,163
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $438.6K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,251,163 · 8
By mechanism
R01$3,051,325 · 2
R21$1,553,590 · 4
K02$420,718 · 1
R29$225,530 · 1
Top collaborators
- Rama Dey-Rao1 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Xin Lin$7,545,603
- Spyridon Stavrou$3,405,261
- Brian Raymond Weil$2,369,417
- Remi Adelaiye-Ogala$2,864,216
- Matthew D Disney$28,195,698
Others in their field
Top investigators on “Dna Binding Protein”
- Barton F Haynes · Duke University$83,177,130
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Michael P Snyder · Yale University$43,587,375
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$34,625,483
- Howard Y Chang · Stanford University$33,145,934
- David Heimbrook · Leidos Biomedical Research, Inc.$28,852,358
Research focus
Dna Binding ProteinVirus DnaDna ReplicationProteinsViralHuman PapillomavirusCellsHelicaseAntiviral AgentsLaboratory RabbitProtein Structure FunctionEnzymesDna Directed Dna PolymeraseGenomeDna BiosynthesisDna DamageMolecular CloningMutantMapsMutationInfectionIn VitroComplexPhosphatidylinositol 3 Kinase
Grant awards (23)
Role of the ETS1 proto-oncogene protein in polyomavirus transcription$240,150
R21 · FY2025 · AI · contact PI
Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets$199,375
R21 · FY2023 · AI · contact PI
Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets$239,250
R21 · FY2022 · AI · contact PI
Slowing of the polyomavirus DNA replication fork in response to DDR$199,375
R21 · FY2022 · AI · contact PI
Slowing of the polyomavirus DNA replication fork in response to DDR$239,250
R21 · FY2021 · AI · contact PI
A novel DNA damage response that inhibits polyomavirus DNA replication$198,128
R21 · FY2018 · AI · contact PI
A novel DNA damage response that inhibits polyomavirus DNA replication$238,062
R21 · FY2017 · AI · contact PI
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics$405,816
R01 · FY2015 · AI · contact PI
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics$405,816
R01 · FY2014 · AI · contact PI
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics$381,467
R01 · FY2013 · AI · contact PI
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics$437,959
R01 · FY2012 · AI · contact PI
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS$331,663
R01 · FY2005 · CA
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS$13,697
R01 · FY2005 · CA
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS$298,496
R01 · FY2004 · CA
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS$264,485
R01 · FY2003 · CA
HPV DNA REPLICATION: NOVEL HOST FACTORS$108,839
K02 · FY2003 · AI
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS$262,795
R01 · FY2002 · CA
HPV DNA REPLICATION: NOVEL HOST FACTORS$106,605
K02 · FY2002 · AI
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS$249,131
R01 · FY2001 · CA
PAPILLOMAVIRUS DNA REPLICATION--HOST CELL FACTORS$115,146
R29 · FY2001 · GM
HPV DNA REPLICATION: NOVEL HOST FACTORS$106,605
K02 · FY2001 · AI
PAPILLOMAVIRUS DNA REPLICATION--HOST CELL FACTORS$110,384
R29 · FY2000 · GM
HPV DNA REPLICATION: NOVEL HOST FACTORS$98,669
K02 · FY2000 · AI